How do you get a GLP-1 for weight loss in Florida?

Key takeaways

Dr. Linda's take

Every week I hear a version of the same question from a Florida patient. "I keep seeing these medications online, how do I actually get one, legitimately, near me?" The honest answer is that getting started is less about geography and more about three things lining up. Whether you meet the clinical criteria, whether you can reach a licensed clinician who can evaluate you, and how you plan to pay for it. Florida does not have a special rulebook here, but it does have specific realities: a large population, a strong telehealth infrastructure, and a patchwork of insurance situations that shape how people actually get started. This article is the overview. I will walk through eligibility, how telehealth access works, and how insurance and cash-pay generally work, and then point you to two more specific guides, one on Florida Medicaid coverage, and one on what Miami and South Florida residents in particular should know.

Who is eligible for treatment?

Eligibility follows the same criteria nationwide, including in Florida, because it is set by FDA-approved labeling rather than by state law. In the United States, GLP-1 medicines approved specifically for chronic weight management are indicated for adults with obesity, generally defined as a body mass index of 30 or higher, or for adults who are overweight, with a body mass index of 27 up to 30, when they also have at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol.

Body mass index is a starting point, not the whole picture. A licensed clinician still needs to review your health history, your current medications, and any conditions that could make a particular medicine a poor fit for you specifically, which is why a real evaluation, not a self-assessment, is the actual gate to a prescription. This is general education, not an individualized recommendation. Whether a specific medicine is right for you is a decision between you and a licensed clinician after a real evaluation.

What's the difference between wegovy, zepbound, ozempic, and mounjaro?

These four brand names create a lot of confusion, so it helps to separate them by what they are actually approved for. The FDA has approved two GLP-1 based medicines specifically for chronic weight management, wegovy (semaglutide) and zepbound (tirzepatide), while ozempic (semaglutide) and mounjaro (tirzepatide) are approved only for type 2 diabetes, so a prescription for either of those two for weight loss alone is considered off-label use.

The active ingredients themselves also work a little differently. Semaglutide, the active ingredient in ozempic and wegovy, activates the GLP-1 receptor, while tirzepatide, the active ingredient in mounjaro and zepbound, activates both the GLP-1 and GIP receptors. GLP-1 receptor agonists work by mimicking a naturally occurring gut hormone, glucagon-like peptide-1, which helps regulate appetite, slows digestion, and supports blood sugar control. Wegovy was approved by the FDA for chronic weight management in 2021, and zepbound followed in 2023 as the first weight-management medicine to activate both the GLP-1 and GIP receptors.

Since ozempic and mounjaro carry a diabetes indication rather than a weight-management one, how a clinician frames the conversation, and how insurance responds, can look meaningfully different compared with wegovy or zepbound, even though the underlying molecules overlap. We unpack how that plays out specifically for Florida Medicaid in our Florida Medicaid coverage guide.

How does telehealth access work for Florida residents?

Telehealth has become a standard way many Florida residents connect with a licensed clinician for a weight-loss evaluation, rather than needing to drive to a brick-and-mortar clinic. A typical path looks like this. You complete an intake covering your health history and goals. A licensed clinician reviews it and, where needed, follows up with you directly. If a prescription weight-loss medicine is clinically appropriate, it is sent to a pharmacy near you or arranged for delivery. The evaluation step is not a formality. It exists so a real clinician, not an algorithm, decides what is appropriate for you and, if so, at what starting dose.

Telehealth tends to matter most for people managing the realities of life in a large, spread-out state: work schedules, distance from a specialist, or simply wanting to start the conversation from home before committing to an in-person relationship. For people in and around Miami and South Florida specifically, including language considerations, we go deeper in our Miami and South Florida guide.

How does insurance and cash-pay coverage generally work?

Coverage is genuinely plan-dependent, and it is one of the most common sources of confusion, so it is worth being direct about the shape of it rather than the specifics of any one plan. Commercial insurance plans vary widely. Some cover wegovy or zepbound for weight management with prior authorization. Some cover the same medicines only when prescribed for a different, coinciding indication like diabetes. Some exclude weight-management drugs from the formulary entirely. Medicaid programs are state-administered and add another layer of variation on top of that, which is exactly why we cover Florida Medicaid on its own in the linked guide above.

Where a plan does not cover the medicine you need, or covers it only partially, cash-pay is the fallback, and manufacturer savings programs exist for eligible patients on the FDA-approved products. The broader coverage landscape for this drug class keeps shifting nationally too, which is worth knowing even though it sits outside Medicaid. In 2026 the Centers for Medicare and Medicaid Services introduced a time-limited demonstration called the Medicare GLP-1 Bridge, offering eligible Medicare Part D beneficiaries access to certain GLP-1 medications for fifty dollars a month between July 2026 and December 2027. That program is specific to Medicare, not Medicaid, but it shows the broader point: coverage rules for this drug class change, so the most reliable step is confirming your own plan's current terms rather than assuming what a friend's plan or a headline covers applies to you.

Is there anything to know about safety before you start?

Yes, and this belongs in any overview of getting started, not buried in the fine print. GLP-1 and GIP-based weight-management medicines carry a boxed warning about the risk of thyroid c-cell tumors, based on findings in rodent studies, and are not recommended for anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. This is exactly the kind of history a real intake and clinician evaluation is designed to catch before a prescription is written, which is another reason the evaluation step matters as much as the eligibility criteria themselves.

Key takeaways

Where do I go from here?

If your main question is about Florida Medicaid specifically, including how weight-loss-only coverage tends to be treated differently from other indications, read our Florida Medicaid coverage guide. If you are based in Miami or South Florida and want to know what to look for in a telehealth provider, including language support, read our Miami and South Florida guide. If you want a structured way to see where you stand before you talk with a clinician, Body Good Studio's quiz is built to walk through your history and goals as a starting point.

Frequently asked questions

Do I need to live near a specialty clinic to start treatment in Florida?

No. Telehealth has made a licensed clinician evaluation accessible from anywhere in the state with an internet connection, so proximity to a specialty clinic is no longer the main factor for most patients.

Is ozempic or mounjaro a legitimate way to pursue weight loss?

They contain the same active ingredients as wegovy and zepbound, but they are FDA-approved for diabetes, not weight management, so a prescription for weight loss alone is off-label. That is a decision for you and a licensed clinician to weigh, not something to decide from an article.

Does Florida require a special license or approval process for telehealth weight-loss visits?

This article covers general clinical and access information rather than state licensing rules, which can change and are best confirmed directly with a licensed telehealth provider. What stays constant is that a real evaluation by a licensed clinician comes before any prescription.

Will my insurance definitely cover this if I qualify clinically?

Not necessarily. Meeting the clinical eligibility criteria and having insurance coverage are two separate questions. Coverage depends on your specific plan, the medicine's FDA-approved indication, and whether your prescription is for weight management or a different condition like diabetes.

What is the first step if I want to explore treatment in Florida?

The first step is a real evaluation, whether through Body Good Studio or another licensed telehealth provider, where a clinician reviews your health history and determines what, if anything, is clinically appropriate for you.

References

1. U.S. Food and Drug Administration / Novo Nordisk Inc. (2024). WEGOVY (semaglutide) injection, for subcutaneous use, full prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5e548d0-cc79-4c34-a3f5-e20a5b8b6564 (Accessed 2026-07-12).
2. U.S. Food and Drug Administration / Eli Lilly and Company (2024). ZEPBOUND (tirzepatide) injection, for subcutaneous use, full prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b (Accessed 2026-07-12).
3. U.S. Food and Drug Administration / Novo Nordisk Inc. (2024). OZEMPIC (semaglutide) injection, solution, full prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79 (Accessed 2026-07-12).
4. U.S. Food and Drug Administration / Eli Lilly and Company (2024). MOUNJARO (tirzepatide) injection, solution, full prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0 (Accessed 2026-07-12).
5. Singh G, Krauthamer M, Bjalme-Evans M (2021). Wegovy (semaglutide): a new weight loss drug for chronic weight management. Journal of Investigative Medicine, 70(1):5-13, PMID 34706925. https://pmc.ncbi.nlm.nih.gov/articles/PMC8717485/ (Accessed 2026-07-12).
6. Abbasi J (2023). FDA green-lights tirzepatide, marketed as zepbound, for chronic weight management. JAMA, 330(22):2143-2144, PMID 37966831. https://pubmed.ncbi.nlm.nih.gov/37966831/ (Accessed 2026-07-12).
7. Centers for Medicare and Medicaid Services (2026). Coming soon: CMS to provide $50 monthly access to GLP-1 medications for Medicare beneficiaries. CMS.gov Newsroom. https://www.cms.gov/newsroom/press-releases/coming-soon-cms-provide-50-monthly-access-glp-1-medications-medicare-beneficiaries (Accessed 2026-07-12).